🚨 IMBIMBO | Novartis Tshayisa Ngemva Kokunye Ukwehluleka Okukhulu Kwezidakamizwa
Amasheya akwaNovartis ehle ngo-8.8% ekuhwebeni eYurophu namuhla ngemuva kokunye okukhulu ukuhlehla emgqeni wawo wezidakamizwa.
Umuthi wawo wokuhlola, i-del-desiran, wehlulekile ukuhlangabezana ne-endpoint eyinhloko esivivinyweni seSigaba sesi-III (Phase III) se-myotonic dystrophy.
Kungani lokhu kubalulekile:
UNovartis wathola umuthi nge-acquisition yakhe ecishe ibe ngu-$12B ye-Avidity, okwenza kube yingxenye ebalulekile yendaba yokukhula yesikhathi esizayo yenkampani.
Futhi akusona isigameko esisodwa esizimele.
Ezinsukwini ezimbalwa nje ezedlule, omunye umuthi kaNovartis obebhekwa eduze, i-pelacarsen, nawo wehlulekile esivivinyweni sokugcina (late-stage).
Ukudumala okukhulu okubili emgqeni wezidakamizwa phakathi kwezinsuku ezimbalwa kubangela abatshalizimali ukuthi baphinde bahlole ukuthi sekuvele kufakwa kuphi kangakanani ukukhula kwesikhathi esizayo kulo.
UNovartis usaqhubeka nokugcina umgomo wakhe wokukhula kwemali engenayo (annual sales growth) ka-5–6% kuze kube ngu-2030.
🇺🇸 I-ticker yase-US okufanele uyiqaphele namuhla: $NVS
Umbuzo omkhulu manje:
Ingabe i-Wall Street izokukubheka lokhu njengokuphazamiseka kwesikhashana emugqeni wezidakamizwa—noma izoqala ukuphinda ibeke intengo kabusha indaba yokukhula yesikhathi eside kaNovartis?
#Stocks #NVS #Novartis #StockMarket #Biotech